COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

NCI expands collaborative partnerships in proteomics research and antibody production/characterization
MOU Extends CPTAC Proteomics Standardized Workflows within an Active Clinical Research Setting

Innovative Molecular Analysis Technologies Program Funding Opportunities

The NCI is very pleased to announce that the Innovative Molecular Analysis Technologies (IMAT) program funding opportunity announcements have been posted for calendar year (CY) 2013. Please visit this website for more information on these announcements. For your convenience, a link to each solicitation is provided below with associated submission deadlines for new applications and resubmissions. Please contact the NCI IMAT program director, Dr.


NIH Seeks Input on Prioritizing Renewable Affinity Reagents

The National Institutes of Health (NIH) is seeking community input on a priority list for renewable affinity reagents for human transcription factors. For more information or to provide input, please visit, http://commonfund.nih.gov/proteincapture/reagents/index.aspx.


Contract Funding Opportunities Available for Innovative SBIR Development

Does your small business need early-stage financing to take its cancer research to the next level? 


CPTAC Launches Proteomics Data Portal

The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) announces the launch of the CPTAC Data Portal. The Data Portal hosts all the data that is currently being produced by the consortium with additional historic data from CPTAC 1. The total amount of hosted data exceeds over 500 GB of RAW data in over 800 files.


Call for Applications – Clinical Assay Development Program

The NCI Clinical Assay Development Program (CADP) is requesting project applications from investigators seeking clinical assay validation resources.  These resources are designed to assist with the development of assays that may predict therapy response or prognostic behavior of a diagnosed cancer, primarily for use in clinical trials. Approved projects for the NCI CADP will be provided access to the Institute’s assay development and validation resources, including project management support.


Advancing Proteomics Research through Collaboration

The National Cancer Institute (NCI), through the Office of Cancer Clinical Proteomics Research (OCCPR), has signed two Memorandums of Understanding (MOUs) in the areas of sharing proteomics reagents and protocols and also in regulatory science.


Omics Workshop Videocast Available

The Omics Integration in Biology and Medicine Workshop, held on June 19th and 20th is now available for viewing on NIH Videocast: Day 1 and Day 2.  The workshop focused on the emerging field of integrating disparate omic data from genomics, proteomics, glycomics, etc. in order to better understand key biological processes and also improve clinical practice.


Omics Integration in Biology and Medicine Workshop

The focus of this meeting will be on the emerging field of integrating disparate omic data from genomics, proteomics, glycomics, etc. in order to better understand key biological processes and also improve clinical practice. Discussants will focus on identifying the technical and biological barriers in omic integration, with solutions to build a consensus towards data integration in bioscience and to better define phenotypes.


NCI Requests Targets for Monoclonal Antibody Production and Characterization

In an effort to provide well-characterized monoclonal antibodies to the scientific community, NCI's Antibody Characterization Program requests cancer-related protein targets for affinity production and distribution.

Submissions will be accepted through July 9, 2012.


Pages